Trial Profile
Exhaled Breath Condensate and Nitric Oxide: Non-Invasive Evaluation of Lung Disease After Treatment With Xolair.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Pharmacodynamics
- Acronyms Xolair-ENO-EBC
- 21 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.
- 05 Jul 2012 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 26 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.